医学
肝细胞癌
射频消融术
队列
内科学
判别式
肿瘤科
烧蚀
人工智能
计算机科学
作者
Masaya Sato,Makoto Moriyama,Toshitaka Fukumoto,Tomoharu Yamada,Taijiro Wake,Ryo Nakagomi,T. Nakatsuka,Tatsuya Minami,Koji Uchino,Kenichiro Enooku,Hayato Nakagawa,Shuichiro Shiina,Kazuhiko Koike,Mitsuhiro Fujishiro,Ryosuke Tateishi
标识
DOI:10.1007/s12072-023-10585-y
摘要
Abstract Introduction Radiofrequency ablation (RFA) is a widely accepted, minimally invasive treatment modality for patients with hepatocellular carcinoma (HCC). Accurate prognosis prediction is important to identify patients at high risk for cancer progression/recurrence after RFA. Recently, state-of-the-art transformer models showing improved performance over existing deep learning-based models have been developed in several fields. This study was aimed at developing and validating a transformer model to predict the overall survival in HCC patients with treated by RFA. Methods We enrolled a total of 1778 treatment-naïve HCC patients treated by RFA as the first-line treatment. We developed a transformer-based machine learning model to predict the overall survival in the HCC patients treated by RFA and compared its predictive performance with that of a deep learning-based model. Model performance was evaluated by determining the Harrel’s c-index and validated externally by the split-sample method. Results The Harrel’s c -index of the transformer-based model was 0.69, indicating its better discrimination performance than that of the deep learning model (Harrel’s c -index, 0.60) in the external validation cohort. The transformer model showed a high discriminative ability for stratifying the external validation cohort into two or three different risk groups ( p < 0.001 for both risk groupings). The model also enabled output of a personalized cumulative recurrence prediction curve for each patient. Conclusions We developed a novel transformer model for personalized prediction of the overall survival in HCC patients after RFA treatment. The current model may offer a personalized survival prediction schema for patients with HCC undergoing RFA treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI